Stock Fundamentals

Company Information

Company Name
4D Molecular Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US35104E1001
CIK: 0001650648
CUSIP: 35104E100
Currency: USD
Full Time Employees: 196
Phone: 510 505 2680
Fiscal Year End: December
IPO Date: Dec 11, 2020
Description:

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Address:

5858 Horton Street, EmeryVille, CA, United States, 94608

Directors & Officers

Name Title Year Born
Dr. John F. Milligan Ph.D. Executive Chairman 1961
Dr. David H. Kirn M.D. Co-Founder, President, CEO & Director 1963
Mr. Kristian Humer M.B.A. CFO and Principal Financial & Accounting Officer 1976
Dr. Fariborz Kamal Ph.D. Chief Technical Advisor 1963
Ms. Theresa Janke Co-Founder & Chief of Staff 1975
Julian Pei Head of Investor Relations & Corporate Finance NA
Dr. Katy Barglow Ph.D. Chief Technical Officer NA
Dr. Scott P. Bizily J.D., Ph.D. Chief Legal Officer & Corporate Secretary 1972
Dr. An Song Ph.D. Chief Translational Medicine Advisor NA
Dr. Noriyuki Kasahara M.D., Ph.D. Chief Scientific Advisor & Member of Scientific Advisory Board 1963

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 20, 2026 Ashoo Gupta N/A Sale 390.00 $8.61 $3.36K
Dec 20, 2025 Ashoo Gupta N/A Sale 389.00 $8.68 $3.38K
Dec 16, 2025 Scott Bizily N/A Sale 1.64K $10.90 $17.82K
Nov 17, 2025 Scott Bizily N/A Sale 1.64K $10.59 $17.31K
Oct 24, 2025 Scott Bizily N/A Sale 2.68K $12.00 $32.14K
Oct 16, 2025 Scott Bizily N/A Sale 1.64K $10.17 $16.63K
Oct 09, 2025 Scott Bizily N/A Sale 2.41K $10.00 $24.08K
Sep 23, 2025 Scott Bizily N/A Sale 2.41K $8.00 $19.26K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HHG PLC 5.25M Mar 31, 2026 10.04% $0.02 13.19%
RA Capital Management, LLC 5.05M Mar 31, 2026 9.66% $0.50 -10.67%
The Goldman Sachs Group Inc 4.21M Mar 31, 2026 8.04% $0.00 -2.27%
BlackRock Inc 4.15M Mar 31, 2026 7.93% $0.00 1.98%
Novo A/S 3.65M Mar 31, 2026 6.98% $2.75 0.00%
Vanguard Group Inc 3.09M Dec 31, 2025 5.92% $0.00 20.13%
Bvf Inc 2.88M Mar 31, 2026 5.51% $0.85 -37.80%
State Street Corp 2.71M Mar 31, 2026 5.18% $0.00 0.71%
Armistice Capital, LLC 2.00M Mar 31, 2026 3.83% $0.33 3.31%
Adage Capital Partners Gp LLC 1.61M Mar 31, 2026 3.07% $0.02 29.96%
Federated Hermes Inc 1.43M Mar 31, 2026 2.74% $0.02 -11.01%
Trails Edge Capital Partners, LP 1.30M Mar 31, 2026 2.49% $2.78 0.00%
Geode Capital Management, LLC 1.07M Mar 31, 2026 2.04% $0.00 5.27%
Bank of America Corp 974.17K Mar 31, 2026 1.86% $0.00 17.01%
Deutsche Bank AG 708.04K Mar 31, 2026 1.35% $0.00 0.54%
Renaissance Technologies Corp 578.27K Mar 31, 2026 1.11% $0.01 12.74%
Nuveen, LLC 561.81K Mar 31, 2026 1.07% $0.00 253.85%
Dimensional Fund Advisors, Inc. 522.82K Mar 31, 2026 1.00% $0.00 77.32%
Parkman Healthcare Partners LLC 522.58K Mar 31, 2026 1.00% $0.50 3.80%
RTW INVESTMENTS, LLC 475.74K Mar 31, 2026 0.91% $0.04 0.00%

Shares Statistics

Shares Outstanding: 52.28M
Shares Float: 38.84M
% Insiders: 354.50%
% Institutions: 9,835.40%
Short % Float: 26.72%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.71M 3.26% ▲ 0.00% Apr 30, 2026
2 iShares Russell 2000 ETF 1.03M 1.97% ▲ 0.85% Apr 30, 2026
3 Janus Henderson Gbl Life Sciences Divers 851.19K 1.63% ▲ 0.00% Sep 30, 2025
4 Janus Henderson Global Life Sciences D 843.75K 1.61% ▲ 0.43% Mar 31, 2026
5 Janus Henderson Global Life Sciences 843.75K 1.61% ▲ 0.15% Mar 31, 2026
6 Janus Global Life Science AUSD 782.98K 1.50% ▲ 5.18% Mar 31, 2026
7 Janus Henderson Glb Life Scn I2 USD 780.76K 1.49% ▼ 0.28% Apr 30, 2026
8 Janus Henderson Hrzn Biotec E2 USD 727.25K 1.39% ▲ 12.10% Mar 31, 2026
9 Federated Hermes MDT Small Cap Core IS 702.45K 1.34% ▼ 6.58% Mar 31, 2026
10 Federated Hermes MDT SCC Institutional 702.45K 1.34% ▼ 6.58% Mar 31, 2026

Valuation Metrics

Enterprise Value: $137.25M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $484.60M
EBITDA: $-171.43M
Book Value: $8.64
Earnings/Share: $-2.57
Profit Margin: -182.34%
Operating Margin: -2,416.15%
ROA (TTM): -21.43%
ROE (TTM): -34.92%
Revenue (TTM): $88.24M
Revenue/Share (TTM): $1.45
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 21,664.30%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 9.39x 0.01x 0.11x N/A -0.04x
2024-12-31 14.92x 0.01x 0.09x N/A -0.03x
2023-12-31 15.65x 0.01x 0.09x N/A -0.03x
2022-12-31 14.02x 0.01x 0.12x -17.14x -0.03x
2021-12-31 15.69x 0.00x 0.10x -23.50x -0.02x
2020-12-31 16.88x 0.00x 0.11x -372.79x 0.00x
2019-12-31 4.05x 0.00x 2.25x N/A 0.00x
2018-12-31 11.68x 0.00x 1.28x N/A -0.01x
2017-12-31 4.15x 0.00x 1.72x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about FDMT.US!